Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

Bio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.

Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected ...

The futures contracts platform aims to meet offshore investors’ heightened interest in Hong Kong-listed Chinese ...

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus.

The investment seeks daily investment results, before fees and expenses, of 200% of the daily performance of the NYSE Biotechnology Index. The fund, under normal circumstances, invests at least 80% of ...

Rani Therapeutics Holdings ($RANI), a clinical-stage penny biotech stock, soared nearly 250% on Friday and continued to trade ...

Galecto stock soars as meme stock enthusiasts flock into the biotech name for no apparent reason. Here’s why GLTO shares are super risky to own at current levels.

Purple Biotech Ltd. ('Purple Biotech” or 'the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance ...